Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Roivant Sciences Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2022
FY2023
FY2023
FY2024
FY2025
Revenue
23.8
55.3
31.5
32.7
29.1
8.26
Research and development
237
483
454
440
550
682
Selling, general and administrative
775
601
687
General and administrative
260
775
383
416
591
610
Operating expenses
1,095
1,407
938
884
1,143
1,294
Operating income
-1,071
-1,352
-907
4,497
-1,003
-515
Interest expense
2.81
7.04
28
34.8
Interest income
1.42
0.37
146
258
178
Other non-operating income
-8.7
3.24
-0.49
-13.6
-10.7
4.01
Pre-tax income
-899
-924
-885
4,568
-682
-265
Income tax
1.69
0.37
4.08
21.5
48.2
133
Income from continuing operations
-845
-784
4,663
-545
-300
Net income to minority interests
-91
-78.9
-106
-118
-185
-98.1
Net income
-809
-845
-1,009
4,349
-172
-300
EBITDA
-1,346
-888
4,519
-989
-512
EPS, basic
-1.28
-1.26
-1.42
5.55
-0.24
-0.43
EPS, diluted
-1.28
-1.26
-1.42
5.23
-0.24
-0.54
Shares, basic (weighted)
630
670
713
783
725
694
Shares, diluted (weighted)
630
670
713
831
725
694
Balance sheet
FY2022
FY2022
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
2,055
2,060
1,677
6,495
2,715
1,419
Short-term investments
0
2,171
2,873
Receivables
11.2
3.88
30.4
3.99
Inventory
0
2.76
35.3
Other current assets
54.3
86.1
122
80.6
113
105
Total current assets
2,187
2,147
1,799
6,732
5,000
5,167
Property, plant and equipment
14.7
25.9
39.1
15.3
12.1
12
Lease right-of-use assets
62.3
61
53.3
44
89
80.4
Intangible assets
0
145
138
Long-term investments
101
0
Other non-current assets
27.2
25.8
49.5
37.7
32.9
40.9
Total assets
2,590
2,585
2,390
7,222
5,437
5,709
Accounts payable
20.6
34.6
37.8
14
23.7
18
Accrued liabilities
76.9
128
167
119
114
206
Deferred revenue
5.92
10.1
12.4
4.17
1.17
Short-term debt
0
0
40.7
12
Total current liabilities
219
184
272
267
149
281
Long-term debt
170
210
Lease liabilities
62.4
62.5
53.5
45
90.3
96.3
Other non-current liabilities
8.17
21.9
17
2.49
0.02
0.07
Total liabilities
528
524
782
774
250
416
Total debt
170
210
376
431
Paid-in capital
3,815
4,422
4,933
5,396
4,562
5,025
Retained earnings
-1,918
-2,764
-3,773
576
116
-502
Other comprehensive income
1.45
-0.95
-2.62
-4.08
9.44
4.36
Shareholders' equity
1,798
1,657
1,158
5,969
4,688
4,527
Minority interests
242
382
450
480
500
765
Total equity
2,040
2,039
1,608
6,449
5,187
5,292
Total liabilities and equity
2,590
2,585
2,390
7,222
5,437
5,709
Shares outstanding
652
695
760
807
696
720
Cash flow statement
FY2022
FY2022
FY2023
FY2023
FY2024
FY2025
Net income
-900
-924
-1,115
4,231
-357
-398
Depreciation and amortization
5.93
18.9
22
14.1
3.35
Stock-based compensation
85
565
218
200
289
346
Deferred income tax
0
0
0
0
0
0
Cash from operations
-552
-678
-843
-765
-839
-750
Capital expenditures
-5.81
-17.4
-12.7
-1.38
-4.6
-8.21
Purchases of investments
0
0
0
-4,796
Sales and maturities of investments
0
320
0
0
0
1,122
Cash from investing
-31.7
303
-44.3
5,204
-1,766
-682
Stock issued
0
312
200
0
0
Share buybacks
0
0
-1,293
Cash from financing
456
307
499
419
-1,220
134
Exchange rate effect
0
6.28
0.62
Net change in cash
-128
-67.6
-382
4,858
-3,825
-1,295
Free cash flow
-558
-695
-856
-767
-844
-759
Interest paid
2.02
5.54
5.3
10.3
5.96
0
Income taxes paid
4.08
0.92
5.13
12.4
61.9
48.4
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $35.80 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-7,915.0%
Operating income / revenue.
EBITDA margin
-7,877.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-3,849.0%
Pre-tax income / revenue.
Net margin
-3,535.0%
Net income / revenue.
FCF margin
-10,901.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-10,840.0%
Cash from operations / revenue.
Return on equity (ROE)
-6.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-5.0%
Net income / average total assets.
Return on invested capital (ROIC)
-15.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
9,704.0%
Research and development expense / revenue.
Stock-based pay / revenue
4,611.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
61.0%
Capital expenditures / revenue.
D&A / revenue
37.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-71.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-36.0%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-19.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-3.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
57.5%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
20.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
5.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
33.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
17.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
-4.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-0.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
1.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
16.7x
Current assets / current liabilities.
Quick ratio
13.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
13.5x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.01
Revenue / diluted weighted shares.
FCF per share
-$1.14
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.13
Cash from operations / diluted weighted shares.
Book value per share
$5.86
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
3,433x
Market cap / revenue.
P/B
6.11x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
6.11x
Market cap / tangible book value, when positive.
EV/Sales
2,923x
Enterprise value / revenue.
FCF yield
-3.2%
Free cash flow / market cap.
Earnings yield
-1.0%
Net income / market cap (the inverse of P/E).
What was Roivant Sciences Ltd.'s revenue in fiscal 2025?
Roivant Sciences Ltd. reported revenue of $8.3M for fiscal 2025, 71.6% lower than the year before.
Was Roivant Sciences Ltd. profitable in fiscal 2025?
No. It reported a net loss of $299.8M.
How much free cash flow did Roivant Sciences Ltd. generate in fiscal 2025?
Cash from operations of $750.3M minus capital expenditures of $8.2M left free cash flow of -$758.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.